NEW YORK, Nov. 12, 2015 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune” or the “Company”) announces corporate update and three months and nine months ended September 30, 2015 financial results.
Recent Highlights, Upcoming Milestones and Third Quarter 2015 Financial Results
Dr. Daniel Teper, CEO of Immune stated, “Over the past few months we have made decisive progress in the clinical development of our lead product candidate and firstin-class monoclonal antibody, bertilimumab, which targets eotaxin-1, a key regulator of immuno-inflammation. We recently announced the acceptance of an Investigational New Drug (IND) application for bullous pemphigoid (BP) by the U.S. FDA. This will allow us to add U.S. clinical sites, including Mount Sinai for our Phase 2 clinical trial and EU sites, upon regulatory clearance there.
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.
